Christina Van Heer

1

Article

0

Comments
Shutterstock

Paxlovid is Australia’s first‑line COVID antiviral but Lagevrio also prevents severe disease in over‑70s

Benjamin Cowie, The Peter Doherty Institute for Infection and Immunity; Brett Sutton, Monash University; Christina Van Heer, The University of Melbourne, and Suman Majumdar, Burnet Institute

Analysis of Victoria’s winter COVID wave found Paxlovid and Lagevrio reduced the risk of hospitalisation and death. The results were better for Paxlovid, but not everyone can take it.

Contact Christina for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration